Sure. I can certainly take that.
The inhaled vaccine really builds on the expertise that we have at McMaster in adenovirus-based technology. The adenovirus-based technology is actually McMaster's solution from many years ago. We also have deep expertise in mucosal immunity. This stems from past research in tuberculosis.
Putting all that expertise together, we came up with a new inhaled type of vaccine that gets directly into the lungs and the mucosal surfaces where we know it is more efficacious. It also is different in that it has three different proteins—not just against spike, but also against two other conserved proteins. This will allow it to provide immunity against variants of concern or even new coronaviruses. Because of the nature of it being an inhaled vaccine, it only requires about 1/100th of the dose. From a manufacturing perspective, this gives a great advantage.
This is all from past investment in our GNP facility and from the research within our group that we were able to develop this really new type of technology.